Risk Assessment
Dr. Farag reviews your personal and family cancer history, existing screenings, and risk factors to confirm test appropriateness.
Galleri Multi-Cancer Early Detection Test in Fort Myers, FL
Screen for 50+ Cancers
Your Galleri Multi-Cancer Early Detection Test at a glance:
Test Type:Blood draw
Cancers Screened:50+ types
Results Time:2-3 weeks
FDA Status:Breakthrough device
Why Standard Cancer Screening Falls Short
The Detection Gap
Despite advances in medicine, cancer remains the second leading cause of death in the United States. The challenge: most cancers are detected only after symptoms appear, when the disease has often already spread and treatment becomes more difficult. Standard cancer screenings exist for only five cancer types - breast (mammogram), cervical (Pap/HPV), colorectal (colonoscopy), lung (low-dose CT for smokers), and prostate (PSA). The remaining 70+ cancer types have no recommended screening test, meaning they're typically found incidentally or at advanced stages when survival rates drop significantly.
The Galleri multi-cancer early detection test at RegalMed Clinic addresses this screening gap. Developed by GRAIL using genomic technology, the Galleri test analyzes cell-free DNA (cfDNA) methylation patterns in your blood to detect cancer signals from over 50 cancer types - including pancreatic, liver, ovarian, esophageal, and head and neck cancers that currently have no standard screening. When a cancer signal is detected, the test also predicts the cancer signal origin (where in the body the cancer likely originated) to guide follow-up diagnostic workup. Dr. Farag integrates this alongside standard screenings for comprehensive cancer surveillance.
What Is the Galleri Test?
Multi-Cancer Blood Screening
The Galleri test is a multi-cancer early detection (MCED) blood test developed by GRAIL, Inc. It works by analyzing cell-free DNA (cfDNA) - fragments of DNA shed by cells (including tumor cells) into the bloodstream. Rather than looking for specific gene mutations, the Galleri test uses targeted methylation analysis to detect patterns of DNA methylation that are characteristic of cancer versus normal tissue. DNA methylation is a chemical modification that affects gene expression and is significantly altered in cancer cells.
The test screens for signals from over 50 cancer types, many of which lack standard screening options. In clinical validation studies (CCGA, PATHFINDER, SYMPLIFY), the Galleri test demonstrated a specificity of 99.5% (very low false positive rate) and the ability to detect cancer signals across all stages, with higher sensitivity for later-stage cancers and a clinically significant detection rate for stage I-III cancers. When a signal is detected, the test provides a Cancer Signal Origin (CSO) prediction, identifying the tissue of origin with approximately 88% accuracy to direct subsequent diagnostic evaluation. The Galleri test received FDA Breakthrough Device designation and is intended as a complement to - not a replacement for - standard cancer screening guidelines.
Treatment Timeline
Blood Draw
Single venipuncture, 10-15 minutes
Lab Processing
cfDNA methylation analysis over 2-3 weeks
Results Review
Consultation with Dr. Farag to discuss findings
Retest Interval
Annually for ongoing cancer surveillance
Benefits of the Galleri Test
Proactive Cancer Screening
- 01
Comprehensive Screening
One blood draw screens for signals from over 50 cancer types simultaneously
- 02
Low False Positive Rate
99.5% specificity means minimal unnecessary follow-up procedures
- 03
Cancer Signal Origin
Predicts where in the body the cancer signal originated with 88% accuracy
- 04
No Standard Screening Gap
Detects cancers that have no other recommended early detection method
- 05
Simple and Fast
Standard blood draw with results in approximately 2-3 weeks
- 06
Complementary Approach
Designed to work alongside existing cancer screenings for maximum coverage
Galleri vs Standard Screenings
Compare Your Options
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| Galleri Test | cfDNA methylation analysis from blood | 10-15 min draw | 2-3 weeks | Annual screening | None | Multi-cancer screening for 50+ types including those with no standard screening |
| Telomere Length Analysis | Quantitative PCR of chromosome telomeres | 10-15 min draw | 2-3 weeks | Annual assessment | None | Measuring biological aging and overall longevity trajectory |
| Standard Cancer Screenings | Mammogram, colonoscopy, Pap, PSA, low-dose CT | Varies by test | Days to weeks | Per guidelines | Varies | Established screening for breast, cervical, colon, lung, prostate cancers |
Who Should Get the Galleri Test?
Candidacy Assessment
The Galleri test is recommended for adults with an elevated risk of cancer who want comprehensive screening beyond what standard guidelines cover. GRAIL recommends the test for adults aged 50 and older, though younger patients with elevated risk factors may also benefit.
Ideal Candidates for the Galleri Test
- Adults aged 50 and older seeking comprehensive multi-cancer screening
- Individuals with strong family history of cancer, especially types with no standard screening
- Patients with known cancer risk factors (smoking history, environmental exposures, prior cancer)
- Health-conscious adults who want the most thorough cancer surveillance available
- Patients already completing standard screenings who want to close the detection gap
Who May Not Benefit from This Test
- Adults under 50 with no cancer risk factors (lower baseline cancer prevalence reduces test utility)
- Patients currently undergoing active cancer treatment (test is designed for screening, not monitoring)
- Individuals who would not pursue diagnostic workup if a cancer signal were detected
Dr. Farag will evaluate your age, family history, and risk factors to determine whether the Galleri test is appropriate for your cancer prevention strategy.
What Happens During Your Test
Blood Draw
A standard venipuncture collects two tubes of blood, which are shipped to GRAIL's CLIA-certified laboratory for processing.
Lab Analysis
GRAIL's lab extracts cell-free DNA from your blood and analyzes methylation patterns using next-generation sequencing technology.
Results Review
Dr. Farag discusses your results: either 'No Cancer Signal Detected' or 'Cancer Signal Detected' with predicted signal origin.
Next Steps
If a signal is detected, Dr. Farag coordinates diagnostic workup and specialist referrals guided by the Cancer Signal Origin prediction.
Side Effects & Important Limitations
What to Know
The Galleri test is a standard blood draw with no systemic side effects. However, understanding the test's clinical limitations is essential for informed decision-making.
Side Effects (Blood Draw Only)
- Minor bruising or tenderness at the venipuncture site
- Brief lightheadedness during or immediately after the draw (rare)
Important Clinical Limitations
- The Galleri test is a screening tool - a positive result (Cancer Signal Detected) requires confirmatory diagnostic testing to confirm or rule out cancer
- A negative result (No Cancer Signal Detected) does not guarantee the absence of cancer; some cancers may not shed detectable levels of cfDNA
- The test has higher sensitivity for later-stage cancers; some early-stage cancers may not produce enough cfDNA for detection
- The Galleri test is intended to complement, not replace, standard cancer screenings (mammography, colonoscopy, Pap smear, PSA, low-dose CT)
- False positives, while rare (0.5%), can lead to additional diagnostic procedures
Dr. Farag will thoroughly explain these limitations during your pre-test consultation, ensuring you have realistic expectations and understand how the Galleri test fits within your complete cancer screening strategy.
Galleri Test Cost in Fort Myers
Cancer Screening Investment
The Galleri multi-cancer early detection test is an investment in comprehensive cancer surveillance that goes far beyond what standard screenings alone can provide.
Pricing Overview
The Galleri test is priced at approximately $949 per test, set by GRAIL. This is a single, transparent price that includes the blood collection kit, laboratory analysis using next-generation sequencing of cfDNA methylation patterns, and the comprehensive results report with Cancer Signal Origin prediction if applicable.
What's Included
- Pre-test consultation and risk assessment with Dr. Farag
- Blood draw and specimen shipping to GRAIL's CLIA-certified laboratory
- Targeted methylation analysis screening for 50+ cancer types
- Cancer Signal Origin prediction if a signal is detected
- Results review consultation with Dr. Farag
- Coordination of diagnostic follow-up if needed
Insurance & Payment
The Galleri test is not currently covered by most insurance plans, including Medicare. GRAIL offers payment plan options for eligible patients. RegalMed Clinic accepts major credit cards and can provide documentation for HSA/FSA reimbursement. Contact our Fort Myers office at (239) 395-2434 to discuss pricing and payment options.
Why Choose RegalMed Clinic
Fort Myers Cancer Screening
Physician-Guided Screening
Dr. Farag personally evaluates your risk profile and guides result interpretation
Comprehensive Follow-Up
Positive signals receive immediate coordination of diagnostic workup and specialist referrals
Integrated Prevention
Galleri testing combined with standard screenings and longevity assessments
Compassionate Communication
Results discussed with clarity, context, and a clear action plan regardless of outcome
Related Services
Advanced Diagnostic Testing
Regenerative Medicine
Galleri Test FAQ
Answers to Your Questions
01 How does the Galleri test work?
The Galleri test analyzes cell-free DNA (cfDNA) in your blood - fragments of DNA shed by cells throughout your body. It uses targeted methylation analysis to detect DNA methylation patterns characteristic of cancer cells. When a cancer signal is detected, the test also predicts the Cancer Signal Origin to guide your doctor's next steps.
02 Does the Galleri test replace my mammogram or colonoscopy?
No. The Galleri test is designed to complement, not replace, standard cancer screenings. You should continue all recommended screenings (mammography, colonoscopy, Pap smear, etc.) in addition to the Galleri test. Together, they provide the most comprehensive cancer surveillance available.
03 What happens if my Galleri test detects a cancer signal?
Dr. Farag will review your results and the predicted Cancer Signal Origin. She will then coordinate confirmatory diagnostic testing - which may include imaging, biopsy, or specialist referral - to determine if cancer is present and its exact location. Early detection significantly improves treatment outcomes for most cancers.
04 What does 'No Cancer Signal Detected' mean?
A 'No Cancer Signal Detected' result means the test did not identify methylation patterns consistent with cancer in your blood sample at the time of testing. This is reassuring but does not guarantee the absence of cancer. Some cancers may not shed enough cfDNA to be detected, which is why maintaining standard screenings remains important.
05 How often should I take the Galleri test?
GRAIL recommends annual testing for ongoing cancer surveillance. Cancer can develop between tests, so annual screening provides the best opportunity for early detection. Dr. Farag will recommend a testing schedule based on your individual risk profile.
06 Is the Galleri test FDA approved?
The Galleri test has received FDA Breakthrough Device designation and is available as a laboratory-developed test (LDT) through GRAIL's CLIA-certified lab. It has been validated in multiple large clinical studies including the CCGA, PATHFINDER, and SYMPLIFY trials, demonstrating strong clinical performance.
Location15750 New Hampshire Ct, STE D
Fort Myers, FL, 33908
Fort Myers, FL, 33908
Phone(239) 395-2434
Schedule Your Galleri Multi-Cancer Early Detection Test Consultation
References
- PubMed (PMID: 35298516) - PATHFINDER study: clinical implementation of a multi-cancer early detection test in a real-world screening population demonstrated feasibility and clinical utility.
- PubMed (PMID: 32886546) - Circulating Cell-Free Genome Atlas (CCGA) study: validation of targeted methylation analysis for multi-cancer early detection with high specificity.
- PubMed (PMID: 36399660) - SYMPLIFY study: evaluation of the Galleri test in symptomatic patients referred for cancer investigation showed significant clinical utility.
- PubMed (PMID: 33329932) - Multi-cancer early detection tests: performance characteristics of cell-free DNA methylation-based approaches across cancer types and stages.
- PubMed (PMID: 34185482) - Cancer Signal Origin prediction accuracy in multi-cancer early detection: clinical validation of tissue-of-origin localization using methylation patterns.